Apotex Granted Summary Judgment In US Pennsaid 2% Infringement Suit
Delaware District Court Case Involved Licensing Deal Signed In 2013
Executive Summary
Apotex has decisively overcome Horizon’s patent infringement suit stemming from its launch of a generic version of the originator’s Pennsaid 2%.
You may also be interested in...
US Appeals Court Refuses To Review Pennsaid 2%
Unsatisfied with a US Court of Appeals upholding a ruling in favor of Teva's Actavis that several Pennsaid 2% patents were invalid, Horizon Therapeutics sought to have the case reheard en banc. However, the request has been refused.
HK inno.N Eyes 2025 Korea Opportunity With mAbxience Denosumab Deal
Ahead of wrapping up a Phase III clinical trial for its proposed biosimilar denosumab candidate later this year, mAbxience has out-licensed marketing rights in Korea to local player HK inno.N, with a patent expiry opportunity in 2025.
Five Big Legal Stories From 2022
Generics Bulletin looks back at a selection of the most significant legal stories from 2022, including a major victory in the UK on the Eliquis blood thinner giant and continued action on generic label carve outs, which has the potential to reverberate through the US industry.